Triple
T11074424
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CD20 protein |
E261827
|
entity |
| Predicate | targetOf |
P860
|
FINISHED |
| Object | ocrelizumab |
E518760
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ocrelizumab | Statement: [CD20 protein, targetOf, ocrelizumab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ocrelizumab Context triple: [CD20 protein, targetOf, ocrelizumab]
-
A.
ocrelizumab
chosen
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
-
B.
Ofatumumab
Ofatumumab is a fully human monoclonal antibody used primarily in the treatment of certain B‑cell malignancies and relapsing forms of multiple sclerosis.
-
C.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d6aa9983c08190b0ef61603b69feac |
completed | April 8, 2026, 7:20 p.m. |
| NER | Named-entity recognition | batch_69d7994e32fc8190a6591d9e82b68f75 |
completed | April 9, 2026, 12:19 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69e3c8cc77988190aad54f56dbd0f8cf |
completed | April 18, 2026, 6:09 p.m. |
Created at: April 8, 2026, 9:26 p.m.